查看所有供应商和价格请点击:
1448327-63-6生产厂家
1448327-63-6价格
化源商城直购
HER3
[1]. Schneeweiss A, et al. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs. 2018 Oct;36(5):848-859.